Home LiteratureArticle Details
PMID: 9797213 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.

Antimicrobial agents and chemotherapy ·Vol. 42 ·No. 11 ·1998-11-00 ·Pages 2841-7

Firsov AA, Vostrov SN, Shevchenko AA, Portnoy YA, Zinner SH

Abstract

Time-kill studies, even those performed with in vitro dynamic models, often do not provide definitive comparisons of different antimicrobial agents. Also, they do not allow determinations of equiefficient doses or predictions of area under the concentration-time curve (AUC)/MIC breakpoints that might be related to antimicrobial effects (AMEs). In the present study, a wide range of single doses of trovafloxacin (TR) and twice-daily doses of ciprofloxacin (CI) were mimicked in an in vitro dynamic model. The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively]. The observation periods were designed to include complete bacterial regrowth, and the AME was expressed by its intensity (the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill and regrowth curves up to the point where viable counts of regrowing bacteria equal those achieved in the absence of drug [IE]). In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively. Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml). The slopes and intercepts of these relationships differed for TR and CI, and the IE-log AUC/MIC plots were not superimposed, although they were similar for all bacteria with a given antibiotic. By using the relationships between IE and log AUC/MIC, TR was more efficient than CI. The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (microg . h/ml)/(microg/ml)] was approximately twofold lower than that for CI. Based on the IE-log AUC/MIC relationships, the respective dose (D)-response relationships were reconstructed. Like the IE-log AUC/MIC relationships, the IE-log D plots showed TR to be more efficient than CI. Single doses of TR that are as efficient as two 500-mg doses of CI (500 mg given every 12 h) were similar for the three strains (199, 226, and 203 mg). This study suggests that in vitro evaluation of the relationships between IE and AUC/MIC or D might be a reliable basis for comparing different fluoroquinolones and that the results of such comparative studies may be highly dependent on their experimental design and datum quantitation.

MeSH Terms
Anti-Infective Agents/pharmacokinetics,pharmacology Bacteria/drug effects,growth & development Ciprofloxacin/pharmacokinetics,pharmacology Dose-Response Relationship, Drug Fluoroquinolones Humans Microbial Sensitivity Tests Naphthyridines/pharmacokinetics,pharmacology
Chemicals
Anti-Infective Agents Fluoroquinolones Naphthyridines Ciprofloxacin trovafloxacin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Firsov A A
Department of Pharmacokinetics, Centre of Science & Technology LekBioTech, Moscow 117246, Russia. Biotec@glas.apc.org
Vostrov S N
Shevchenko A A
Portnoy Y A
Zinner S H
References (25)
25 references, click to expand
  1. Influence of ampicillin elimination half-life on in-vitro bactericidal effect.
    J Antimicrob Chemother. 1985 Jan;15 Suppl A:257-60 PMID: 3980329
  2. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
    Antimicrob Agents Chemother. 1998 Mar;42(3):659-65 PMID: 9517948
  3. The comparative pharmacokinetics of five quinolones.
    J Antimicrob Chemother. 1986 Nov;18 Suppl D:71-81 PMID: 3468102
  4. In vitro models for the study of antibiotic activities.
    Prog Drug Res. 1987;31:349-81 PMID: 3326034
  5. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.
    Antimicrob Agents Chemother. 1990 Jul;34(7):1312-7 PMID: 2117416
  6. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.
    J Antimicrob Chemother. 1990 Jul;26(1):71-9 PMID: 2211449
  7. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
    DICP. 1991 Oct;25(10):1050-7 PMID: 1803788
  8. In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage.
    Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:406-9 PMID: 1820913
  9. Pharmacokinetic considerations in quinolone therapy.
    Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):34S-38S PMID: 8474936
  10. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
    Antimicrob Agents Chemother. 1993 May;37(5):1073-81 PMID: 8517694
  11. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
    Antimicrob Agents Chemother. 1993 Nov;37(11):2454-8 PMID: 8285633
  12. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
    Antimicrob Agents Chemother. 1994 Dec;38(12):2702-9 PMID: 7695250
  13. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
    J Antimicrob Chemother. 1995 Aug;36(2):385-94 PMID: 8522468
  14. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Drugs. 1995;49 Suppl 2:194-6 PMID: 8549301
  15. Pharmacodynamics of quinolones.
    Drugs. 1995;49 Suppl 2:197-9 PMID: 8549302
  16. Comparison of the pharmacodynamic properties of quinolones.
    Drugs. 1995;49 Suppl 2:269-71 PMID: 8549328
  17. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6 PMID: 8619569
  18. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa.
    J Antimicrob Chemother. 1996 Apr;37(4):703-10 PMID: 8722536
  19. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
    Antimicrob Agents Chemother. 1996 Jan;40(1):47-9 PMID: 8787877
  20. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Antimicrob Agents Chemother. 1996 Mar;40(3):627-32 PMID: 8851583
  21. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.
    Antimicrob Agents Chemother. 1996 Mar;40(3):734-8 PMID: 8851602
  22. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
    Antimicrob Agents Chemother. 1997 Jun;41(6):1281-7 PMID: 9174184
  23. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    J Antimicrob Chemother. 1997 Jun;39 Suppl B:43-9 PMID: 9222069
  24. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    J Antimicrob Chemother. 1997 Nov;40(5):639-51 PMID: 9421311
  25. Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
    Antimicrob Agents Chemother. 1985 Mar;27(3):375-9 PMID: 3158275
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1998-11-00
Pages
2841-7
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC105953
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com